KIT and gastrointestinal stromal tumor: Short-term antiproliferative activity showed values similar to imatinib, the reference drug for GIST treatment, in GIST cell lines (IC50 1.6 μM, Table 4); moreover, the NDI was able to reduce KIT transcription by 90% and to completely inhibit KIT expression at the same dosage level required to obtain antiproliferative effect in cells.